Genotype | Male controls 421 [N(%)] | Prostate cancer 329 [N(%)] | OR (95% CI) | P |
---|---|---|---|---|
28/44 | 0 (0.00) | 1 (0.30) | - | 0.2576 |
37/44 | 0 (0.00) | 1 (0.30) | - | 0.2576 |
39/42 | 1 (0.24) | 1 (0.30) | 1.28 (0.08-20.5) | 0.8611 |
39/44 | 0 (0.00) | 3 (0.91) | - | 0.0496* |
40/42 | 0 (0.00) | 1 (0.30) | - | 0.2576 |
40/44 | 1 (0.24) | 1 (0.30) | 1.28 (0.08-20.5) | 0.8611 |
42/42 | 54 (12.83) | 37 (11.25) | 0.86 (0.55-1.34) | 0.5107 |
42/43 | 6 (1.43) | 6 (1.82) | 1.28 (0.41-4.02) | 0.6660 |
42/44 | 192 (45.61) | 150 (45.59) | 1.00 (0.75-1.34) | 0.9972 |
43/44 | 15 (3.56) | 7 (2.13) | 0.59 (0.24-1.46) | 0.2477 |
44/44 | 152 (36.10) | 121 (36.79) | 1.03 (.076-1.39) | 0.8491 |
C/C | 419 (99.52) | 321 (97.57) | 5.22 (1.10-24.76) | |
C/R | 2 (0.48) | 8 (2.43) | P = 0.02* |